The NADPH oxidase inhibitor Vas2870 prevents myocyte ferroptosis and improves cardiac remodelling and function in doxorubicin‐induced cardiomyopathy
Vas2870 prevents myocyte ferroptosis through inhibition of lipid peroxidation, GPX4/SLC7A11 downregulation and disruptions in iron metabolism, leading to the amelioration of doxorubicin-induced heart failure. Therapies directed at inhibiting NADPH oxidase and/or ferroptosis may be of value in the treatment of heart failure.
Authors
- Jia‐Pu Wang
- Xiaojuan Zhang (ORCID: https://orcid.org/0000-0002-4441-0197)
- Fu‐Zhong Qin (ORCID: https://orcid.org/0000-0002-4260-6583)
- Yi-Xiang Wang (ORCID: https://orcid.org/0000-0002-4021-4228)
- Hui‐Ping Zhao
- Bao Li
- Run‐Nan Tantai
- Bin Yang
- Chen‐Mo‐Zhen Li
- Fei Wang
- Hong‐Xia Guo
Institutions
- Shanxi Medical University (CN)
- Second Hospital of Shanxi Medical University (CN)
- Shanxi Cardiovascular Hospital (CN)
Publication Details
- Journal
- British Journal of Pharmacology
- Published
- 2026-02-11
- DOI
- https://doi.org/10.1111/bph.70352
- Primary Topic
- Chemotherapy-induced cardiotoxicity and mitigation
- Type
- article
- Field-Weighted Citation Impact
- 0.00